Navigation Links
Metamark Genetics Board of Directors Appoints Shawn M. Marcell President and Chief Executive Officer
Date:4/30/2013

CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Metamark Genetics, Inc., a leader in the discovery of novel molecular prognostic and diagnostic tests for cancer, today announced that industry veteran Shawn M. Marcell has been named the company's new president and chief executive officer. Mr. Marcell succeeds interim executive Michael Kauffman , M.D., who will remain on Metamark's board of directors. 

Metamark lead director Gregory C. Critchfield , M.D., said, "We are excited to welcome Shawn to Metamark as the company prepares to launch its first prognostic test, for prostate cancer. Shawn's broad and deep experience in life sciences, and his success in bringing innovative products to market, make him the ideal leader for Metamark as it grows into to a commercial organization."  Dr. Critchfield added, "We also would like to thank Michael Kauffman for his leadership during this important time in the company's evolution."

"Metamark's strategy to develop novel prognostic and diagnostic tests based on advanced quantitative histologic analysis has the potential to transform approaches to cancer and other major diseases," said Mr. Marcell. "I am thrilled to join the company and look forward to working with the entire team as we build a leading commercial stage molecular diagnostics company."

Mr. Marcell has nearly three decades of diverse executive, commercial and operational experience in life science and technology businesses. Most recently, he was the lead executive, serving as general manager of Hologic's (HOLX) wholly owned LIFECODES subsidiary, which was acquired by Immucor. He headed commercial operations at Sequenom (SQNM), which acquired SensiGen, where he served as president and CEO. Mr. Marcell has both CLIA laboratory and product launch experience and has had additional key management roles with Redpoint Bio, Prima Facie, Centocor and Abbott Diagnostics.

Mr. Marcell has been adjunct faculty and lecturer in Entrepreneurial Programs at the Wharton School and has served on numerous for-profit and non-profit boards.

About Metamark

Metamark Genetics is a privately held biotechnology company founded in 2007 to develop new function- based prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon and breast cancers. During 2013, Metamark plans to commercialize ProMarkTM – its lead prostate cancer prognostic test – through its Cambridge, MA CLIA-certified laboratory.  For more information, please visit the company's Website at www.metamarkgenetics.com.

MetamarkTM and ProMarkTM are trademarks of Metamark Genetics, Inc.

 

 

 


'/>"/>
SOURCE Metamark Genetics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Intermountain Healthcare and Myriad Genetics Enter Into Research Collaboration Agreement
2. Genelex Receives First Patent on Business Methods for Pharmacogenetics
3. Response Genetics, Inc. to Release Second Quarter Financial Results and Host Conference Call on August 14, 2012
4. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
5. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
6. The International Serious Adverse Event Consortium and UC San Diego To Collaborate On Research Into The Genetics Of Drug Induced Renal Injury
7. Submit Questions to Nobel Laureates and Other Experts about Genetics and Society
8. Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
9. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
10. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
11. NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):